Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
TuBerculosis Vaccine Initiative · South African Tuberculosis Vaccine Initiative · +21 more institutions
Abstract
Background Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. Methods From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with M. tuberculosis infection (defined by positive results on interferon- release assay) without evidence of active tuberculosis disease at centers in Kenya, South Africa, and Zambia. Participants were randomly assigned in a 1:1 ratio to receive two doses of…
Citation impact
- FWCI
- 33.12
- Percentile
- 100%
- References
- 9
Authors
27- DTDereck TaitCorresponding
TuBerculosis Vaccine Initiative, South African Tuberculosis Vaccine Initiative
- MHMark Hatherill
TuBerculosis Vaccine Initiative, South African Tuberculosis Vaccine Initiative
- OVOlivier Van Der Meeren
TuBerculosis Vaccine Initiative, GlaxoSmithKline (Belgium), South African Tuberculosis Vaccine Initiative
- AMAnn M. Ginsberg
International AIDS Vaccine Initiative, TuBerculosis Vaccine Initiative, South African Tuberculosis Vaccine Initiative
- EVElana van Brakel
University of Cape Town, TuBerculosis Vaccine Initiative, Task Applied Science, South African Tuberculosis Vaccine Initiative
Topics & keywords
- Immunogenicity
- Medicine
- Tuberculosis
- Pulmonary tuberculosis
- Mycobacterium tuberculosis
- Immunology
- Pathology
- Immune system
- Good health and well-being